Comparing the current results to its competitors, Qsam Biosciences Inc reported Revenue decrease in the 4 quarter 2023 year on year by 0 %, slower than the combined decrease of the APGR's competitors by -42.14 %, recorded in the same quarter.
Qsam Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as academic and governmental research institutions. Competitors developing targeted alpha-based radiopharmaceuticals for cancer treatment include Bayer AG, Actinium Pharmaceuticals, Inc., RadioMedix, Inc., Orano Med, Telix, Fusion Pharmaceuticals Inc., and RayzeBio, Inc. Bayer's Xofigo is recognized as the first approved alpha particle-based therapy. Companies developing beta particle-based radiopharmaceuticals include POINT Biopharma, Ipsen S.A., Y-mAbs Therapeutics, Inc., and Clovis Oncology, Inc. Many competitors possess greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Smaller or early-stage companies may also present competition, particularly through collaborations with larger firms. Competition extends to recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies and materials. The company acknowledges the risk that competitors may develop safer or more effective drugs with fewer or less severe side effects, potentially reducing its commercial opportunities.
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.
Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of targeted alpha therapeutics for the treatment of cancer. Their business model revolves around harnessing the power of radiation to selectively kill cancer cells while sparing healthy tissues. By combining targeted alpha therapy with various cancer-targeting agents, they aim to develop innovative treatments that offer improved efficacy and reduced side effects for patients.
Rayzebio Inc is a biotechnology company that operates on a business model focused on developing innovative cancer therapies by leveraging cutting-edge technologies and advanced research methods. They aim to identify and target key biological pathways to provide personalized treatment options for patients, ultimately improving cancer outcomes.
Sources:
Qsam Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Qsam Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
